A Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE). This evidence concerns the gene ERBB2 and breast carcinoma.